ESETEC® 2.0 Market Launch: WACKER Achieves Successful Results in Project with MedImmune

Om översättning önskas till svenska, kontakta marie-louise.kaervedal@wacker.com.Munich / Jena, October 21, 2014 – Wacker Biotech GmbH, a subsidiaryof the WACKER Group, has recently completed a feasibilitystudy with MedImmune, the global biologics research anddevelopment arm of AstraZeneca, for an antibody fragment usingWACKER’s improved proprietary secretion technology,ESETEC® 2.0. MedImmune commissioned this work in an effortto identify a cost-effective methodology for antibody fragmentproduction for future therapies. The yields achieved with thisenhanced version of the E.